CONMED Corporation (CNMD) Stock Price & Analysis
CONMED Corporation (CNMD) is trading at USD 44.89, down 1.90% today, as of October 29, 2026 at 14:00 UTC (US market open; quotes may be delayed), according to Nexqual market data.
CNMD last closed at USD 45.76; today's session has ranged USD 43.94–46.09 on volume of 31,781 shares. Market capitalization is $1.34B, with a 52-week range of USD 31.44–53.66 (NYQ). Source: Nexqual, retrieved October 29, 2026 at 14:00 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CNMD.md
Latest Earnings Results (CNMD)
CONMED Corporation (CNMD) reported Q3 2026 results on Oct 28, 2026, 4:08:52 PM ET: adjusted EPS $1.04 vs. estimate $1.00 (beat), revenue $335.56M vs. estimate $336.25M (miss). Guidance: The Company updated its full year 2026 financial guidance for net sales and adjusted diluted EPS. Source: SEC 8-K filing. Nexqual published it 38 seconds after release. Read the SEC filing.
| Fiscal period | EPS (reported) | Revenue | Released | Source |
|---|---|---|---|---|
| Q3 2026 | $1.04 (adjusted (non-GAAP) diluted) | $335.6M | Oct 28, 2026, 4:08:52 PM ET · on Nexqual +38 seconds | SEC 8-K filing |
Reported actuals captured by Nexqual from SEC 8-K filings and company press releases; each figure confirmed by two independent extraction methods.
Key facts (CNMD)
- Last four reported quarters (through Sep 30, 2026): revenue $1.39B, net income $62.5M (4.5% margin) (SEC filings).
- Valuation: P/E 21.5x (avg 32.2x at the last 3 fiscal year-ends), net debt $768M.
- Analysts: Hold (mean 3.29 on a 1–5 scale) (7 analysts), mean target USD 45.5 (range 43–49).
- Total return with dividends: 1Y -3.9% vs S&P 500 +13.0%; 5Y -68.1% vs S&P 500 +78.9%.
- Next earnings: 2027-01-27, EPS estimate USD 1, revenue estimate $336M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CNMD)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.01B | $1.05B | $1.24B | $1.31B | $1.37B | $1.39B |
| Gross profit | $568M | $571M | $676M | $733M | $750M | — |
| Operating income | $110M | $70.1M | $121M | $200M | $103M | $122M |
| Net income | $62.5M | -$80.6M | $64.5M | $132M | $47.1M | $62.5M |
| EPS (diluted) | $1.94 | -$2.68 | $2.04 | $4.25 | $1.51 | — |
| Free cash flow | $96.9M | $11.6M | $106M | $154M | $151M | — |
| Gross margin | 56.2% | 54.6% | 54.3% | 56.1% | 54.6% | — |
| Operating margin | 10.9% | 6.7% | 9.7% | 15.3% | 7.5% | 8.8% |
| Net margin | 6.2% | -7.7% | 5.2% | 10.1% | 3.4% | 4.5% |
| Revenue growth | +17.2% | +3.4% | +19.1% | +5.0% | +5.2% | — |
| Cash + short-term investments | $20.8M | $28.9M | $24.3M | $24.5M | $40.8M | — |
| Total debt | $685M | $1.05B | $974M | $906M | $835M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Sep 30, 2026) (CNMD)
P/E 21.5x · P/S 1.0x · EV/Sales 1.5x · P/B 1.3x · Earnings yield 4.65% · Net debt $768M · EV $2.11B
P/E at fiscal year-ends: Dec 2025 26.9x, Dec 2024 16.1x, Dec 2023 53.6x.
Analysts (CNMD)
Consensus Hold (mean 3.29 on a 1–5 scale), 7 analysts; mean target USD 45.5 (low 43, high 49).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-30 | Piper Sandler | Target raised | Neutral | $39 → $45 |
| 2026-07-30 | Wells Fargo | Target raised | Equal-Weight | $39 → $46 |
| 2026-07-09 | BMO Capital | Initiated | Market Perform | $36 |
Total return (dividends reinvested) (CNMD)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -3.9% | -68.1% |
| S&P 500 (SPY) | +13.0% | +78.9% |
| Per year | -3.9% | -20.4% |
| Volatility (annualized) | 44.8% | 38.0% |
| Max drawdown | -31.3% (Oct 2025→Jun 2026) | -78.4% (Nov 2021→Jun 2026) |
CNMD earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | $1.38 | $1.11 | Beat +24.3% | — |
| — | Quarter ended Mar 31, 2026 | $0.89 | $0.82 | Beat +8.5% | — |
| — | Quarter ended Dec 31, 2025 | $1.43 | $1.32 | Beat +8.3% | — |
| — | Quarter ended Sep 30, 2025 | $1.08 | $1.05 | Beat +2.9% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
CNMD recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 28, 2026 | 10-Q | Quarterly report · period ended Sep 30, 2026 |
| Oct 28, 2026 | 8-K | Quarterly results |
| Jul 29, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Jul 29, 2026 | 8-K | Quarterly results |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
CNMD analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $1.00 | $1.02 | -1.5% | $336.3M | 7 |
| Next quarter (ends Dec 2026) | $1.27 | $1.30 | -2.9% | $369.0M | 7 |
| Current fiscal year (ends Dec 2026) | $4.54 | $4.34 | +4.6% | $1.37B | 7 |
| Next fiscal year (ends Dec 2027) | $4.78 | $4.72 | +1.3% | $1.43B | 7 |
Key Statistics (as of October 29, 2026 at 14:00 UTC)
| Price | USD 44.89 |
|---|---|
| Change | ▼ 1.90% (down) |
| Previous Close | USD 45.76 |
| Open | USD 43.6 |
| Day Range | USD 43.94 – 46.09 |
| 52-Week Range | USD 31.44 – 53.66 |
| Volume | 31,781 shares |
| Market Cap | $1.34B |
| Exchange | NYQ |
Technical Analysis (CNMD)
Nexqual's technical model rates CNMD "SELL" based on 2 bullish and 4 bearish signals across 128 daily candles, as of October 29, 2026 at 14:00 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 43.16 (neutral) |
| vs SMA50 | Below (USD 47.2) |
| MACD | 0.07 (positive) |
Analyst Ratings (CNMD)
Wall Street analysts rate CNMD "Hold" based on 7 analysts, with a mean price target of USD 45.5 (range USD 43–49), per Nexqual as of October 29, 2026 at 14:00 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 45.5 |
| High Target | USD 49 |
| Low Target | USD 43 |
| Buy / Hold / Sell | 0 / 6 / 1 |
Earnings (CNMD)
| Next Earnings Date | 2027-01-27 |
|---|---|
| EPS Estimate | USD 1 |
| Revenue Estimate | $336.25M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.38 vs est 1.11 ▲ beat |
| 2026-03-31 | USD 0.89 vs est 0.82 ▲ beat |
| 2025-12-31 | USD 1.43 vs est 1.32 ▲ beat |
| 2025-09-30 | USD 1.08 vs est 1.05 ▲ beat |
Source: Nexqual, October 29, 2026 at 14:00 UTC.
Financials & Fundamentals (CNMD)
| Total Revenue | $1.37B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +0.30% |
| Gross Margin | +55.58% |
| Operating Margin | +14.64% |
| Profit Margin | +4.12% |
| ROE | +5.53% |
| Debt / Equity | 0.8 |
| Current Ratio | 1.48 |
| Total Cash | $37.33M |
| Total Debt | $834.25M |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | $150.88M (11.0% of revenue) |
Source: Nexqual, October 29, 2026 at 14:00 UTC.
Financial Health Score (CNMD)
Nexqual rates CONMED Corporation's overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 14:00 UTC.
| Growth | Solid — Revenue +5% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 55%, operating 9% (last 4 quarters to Sep 2026, SEC) |
| Balance Sheet | Mixed — $48M cash and investments vs $816M debt (Sep 2026, SEC) |
| Cash Flow | Solid — FCF $151M (FY ended Dec 2025, 10-K), 11% margin |
| Efficiency | Mixed — ROE 6%, ROA 2.7% (last 4 quarters, SEC) |
Ownership (CNMD)
| Insider Ownership | +0.43% |
|---|---|
| Institutional Ownership | +116.69% |
| Shares Outstanding | 29.95M |
| Float | 29.66M |
| Short % of Float | +7.59% |
Source: Nexqual, October 29, 2026 at 14:00 UTC.
Leadership (CNMD)
CONMED Corporation is led by Patrick J. Beyer, President, CEO & Director, per Nexqual as of October 29, 2026 at 14:00 UTC.
| President, CEO & Director | Patrick J. Beyer |
|---|---|
| Executive Vice President of Strategy & Corporate Development | Peter K. Shagory |
| Executive VP, CFO and Principal Financial & Accounting Officer | John E. Gallagher |
| Vice President of Compliance | Keith Seaton |
| Executive Vice President of Human Resources | John David Ferrell |
Major Backers & Investors (CNMD)
Notable institutional backers of CONMED Corporation include Earnest Partners LLC, Fuller & Thaler Asset Management Inc., Bank of America Corporation, according to Nexqual as of October 29, 2026 at 14:00 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Earnest Partners LLC | 8.36% |
| Fuller & Thaler Asset Management Inc. | 5.27% |
| Bank of America Corporation | 4.48% |
| UNDISCOVERED MANAGERS Fd.S-Undiscovered Managers Behavioral Value Fd. | 4.4% |
| SEI Investments Co | 3.3% |
| Invenomic Capital Management, LP | 2.81% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 16.1% |
| Vanguard Group | 11.84% |
| State Street | 4.73% |
| Dimensional Fund Advisors | 4.4% |
Source: Nexqual, October 29, 2026 at 14:00 UTC.
From CONMED Corporation's Latest SEC 10-K Filing (filed 2026-02-17)
Key Strengths & Strategy (as disclosed to the SEC)
- We also pursue organic growth by focusing on our differentiated products.
- We believe that working relationships with physicians and others in the medical industry enable us to gain an understanding of trends and emerging opportunities.
- Active participation allows us to quickly respond to the changing needs of physicians and patients.
Legal & Regulatory Risks (Item 1A, quoted)
- We also must comply with a variety of other laws that impose extensive tracking and reporting related to all transfers of value provided to certain healthcare professionals and others. Any failure to comply with these laws and regulations could subject us or our officers and employees to criminal and civil financial penalties.
- We are subject to various U.S. federal, state and foreign healthcare laws and regulations, which could increase compliance costs, and our failure to comply with these laws and regulations could harm our reputation, subject us to significant fines and liability or otherwise adversely affect our business.
- Failure to comply with regulatory requirements may result in recalls, loss of revenues, fines or other materially adverse implications.
- We incur significant costs to comply with regulations, including the EU MDR. Legal and regulatory requirements and policies are subject to change, which could impose additional or different regulatory requirements on us that could increase the costs of compliance, delay approvals, or otherwise negatively affect our business.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ATEC | Alphatec Holdings, Inc. | USD 11.63 | ▲ 1.57% |
| ESTA | Establishment Labs Holdings Inc | USD 68.86 | ▼ 0.16% |
| BFLY | Butterfly Network, Inc. | USD 7.73 | ▼ 1.02% |
| INSP | Inspire Medical Systems, Inc. | USD 71.55 | ▲ 0.82% |
| UFPT | UFP Technologies, Inc. | USD 289.9 | ▲ 1.36% |
| TMDX | TransMedics Group, Inc. | USD 68.58 | ▲ 2.51% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 14:00 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt